Bicycle Therapeutics was founded in 2009 based on innovative science conducted in the laboratory of the globally respected Professor Sir Greg Winter – a Nobel Prize winner – to translate first-in-class Bicycles into transformative medicines for life-altering diseases.
Its proprietary bicyclic peptide (Bicycle®) product platform has captured attention from Big Pharma and cancer practitioners alike. In June 2019 the company raised $60.6 million via an IPO on the US technology market, Nasdaq.
Bicycle Therapeutics develops cancer drugs that are made from chains of amino acids, called peptides, which form in two loops – hence the company’s name – in order to stabilise their geometry.
They are unique in that they can bind to just about any biological structure, including proteins, and change their function. And because they can act on diseased cells while leaving healthy cells intact, they can attach to the protein of a tumour cell, for example, and prevent it from growing without affecting the neighbouring tissue.
Bicycle’s drugs have a vast range of possible therapeutic applications: cancer; respiratory, cardiovascular and metabolic diseases; psychiatric disorders; and haemophilia.